Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P.

PLoS Pathog. 2010 Feb 26;6(2):e1000796. doi: 10.1371/journal.ppat.1000796.

2.

A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.

Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, Suzich JA, Blair WS, Jin H, Zhu Q.

J Virol. 2014 Jun;88(12):6743-50. doi: 10.1128/JVI.03562-13. Epub 2014 Apr 2.

3.

Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.

Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P.

J Virol. 2014 Dec;88(23):13580-92. doi: 10.1128/JVI.02289-14. Epub 2014 Sep 10.

4.

Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, García-Sastre A, Palese P.

J Virol. 2013 Oct;87(19):10435-46. doi: 10.1128/JVI.01715-13. Epub 2013 Jul 31.

5.

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.

Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A.

PLoS Pathog. 2009 Mar;5(3):e1000350. doi: 10.1371/journal.ppat.1000350. Epub 2009 Mar 20.

6.

Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.

Iba Y, Fujii Y, Ohshima N, Sumida T, Kubota-Koketsu R, Ikeda M, Wakiyama M, Shirouzu M, Okada J, Okuno Y, Kurosawa Y, Yokoyama S.

J Virol. 2014 Jul;88(13):7130-44. doi: 10.1128/JVI.00420-14. Epub 2014 Apr 9.

7.

A highly conserved neutralizing epitope on group 2 influenza A viruses.

Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J.

Science. 2011 Aug 12;333(6044):843-50. doi: 10.1126/science.1204839. Epub 2011 Jul 7.

8.

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.

Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84. doi: 10.1073/pnas.1013387107. Epub 2010 Oct 18.

9.

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F.

J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

10.

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.

Tan GS, Leon PE, Albrecht RA, Margine I, Hirsh A, Bahl J, Krammer F.

PLoS Pathog. 2016 Apr 15;12(4):e1005578. doi: 10.1371/journal.ppat.1005578. eCollection 2016 Apr.

11.

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ.

Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517. Epub 2010 Jul 15.

12.

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, García-Sastre A, Palese P, Treanor JJ, Krammer F.

J Virol. 2013 Apr;87(8):4728-37. doi: 10.1128/JVI.03509-12. Epub 2013 Feb 13.

13.

Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.

Wohlbold TJ, Chromikova V, Tan GS, Meade P, Amanat F, Comella P, Hirsh A, Krammer F.

J Virol. 2015 Oct 28;90(2):851-61. doi: 10.1128/JVI.02275-15.

14.

A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P.

J Virol. 2012 Jun;86(11):6179-88. doi: 10.1128/JVI.00469-12. Epub 2012 Apr 4.

15.

Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.

Gong X, Yin H, Shi Y, He X, Yu Y, Guan S, Kuai Z, Haji NM, Haji NM, Kong W, Shan Y.

Emerg Microbes Infect. 2016 May 25;5:e51. doi: 10.1038/emi.2016.51.

16.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

17.

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F.

MBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15.

18.

Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.

Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, Boyington JC, Nabel GJ.

Sci Transl Med. 2012 Aug 15;4(147):147ra114. doi: 10.1126/scitranslmed.3004273.

19.

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.

De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, Sun X, Tumpey TM, Gubareva LV, Mishin V, Clementi M, Burioni R.

PLoS One. 2012;7(4):e34415. doi: 10.1371/journal.pone.0034415. Epub 2012 Apr 4.

20.

Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.

Hervé PL, Lorin V, Jouvion G, Da Costa B, Escriou N.

Virology. 2015 Dec;486:134-45. doi: 10.1016/j.virol.2015.08.033. Epub 2015 Oct 1.

Supplemental Content

Support Center